MAG
LFCR icon

Millrace Asset Group’s Lifecore Biomedical LFCR Stock Holding History

Millrace Asset Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-47,261
Closed -$376K – 83
2020
Q2 		$376K Buy
+47,261
New +$488K 0.38% 69

Other funds holding LFCR

LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return

Millrace Asset Group's LFCR Position: Q3 2020 in Review

Millrace Asset Group sold out of Lifecore Biomedical (LFCR) in Q3 2020, closing a stake of 47,261 shares — an estimated $376K sold.

Millrace Asset Group first reported a position in LFCR in Q2 2020 and held it in 1 quarter. The position peaked at $376K in Q2 2020. 96 funds tracked by Wall St. Rank hold LFCR as of Q3 2020.

  • Millrace Asset Group reported no remaining Lifecore Biomedical position as of Q3 2020 after selling out during the quarter.
  • Millrace Asset Group sold 47,261 Lifecore Biomedical shares in Q3 2020, an estimated $376K.
  • Millrace Asset Group first reported a position in Lifecore Biomedical in Q2 2020 and held it in 1 quarter.
  • Millrace Asset Group's Lifecore Biomedical position peaked at $376K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2020.

Based on Millrace Asset Group's 13F filing for Q3 2020, filed 17 Nov 2020.